IGLON5 and Sleep apnea: The first cases of patients presenting i.a. severe air-flow disturbance in the respiratory tract and sleep apnea concurrently with the presence of anti-IgLON5 in cerebrospinal fluid (CSF) or serum were described in 2014 (6, 7).